publication date: Jun. 10, 2016
CHICAGO—Vice President Joe Biden June 6 announced the NCI Genomic Data Commons as part of the National Cancer Moonshot Initiative.
The GDC, a $20 million portal that consolidates NCI’s diverse datasets, contains genomic sequences and analyses of tumors, as well as clinical data on enrollment and treatment.
Biden’s announcement—made hours before his address at the 2016 annual meeting of the American Society of Clinical Oncology—establishes NCI as the leader in a high-stakes debate over who gets to set standards for how health records data should be aggregated and organized.
• Related Coverage of the Cancer Moonshot
Vice President Joe Biden challenged individual organizations and leading initiatives in oncology bioinformatics to interoperate and share data.
Speaking at the annual meeting of the American Society of Clinical Oncology in Chicago, Biden announced the NCI’s Genomic Data Commons as part of the National Cancer Moonshot Initiative, and urged others to collaborate with NCI.
The FDA Oncology Center of Excellence—first proposed in the National Moonshot Cancer Initiative—is gaining support from oncology groups as well as in both chambers of Congress.
Earlier this week, 28 oncology professional societies and advocacy organizations sent a letter to FDA Commissioner Robert Califf, describing the organizational structure they’d like to see in the proposed center.
The Senate Committee on Appropriations marked up a bipartisan spending bill June 9 that gives NIH a $2 billion increase in the 2017 fiscal year.
NCI is to receive a $216 million increase over FY 2016.
Passed on a 29-1 vote, the measure boosts the NIH budget to $34 billion and now moves to consideration by full Senate. Funding for the Centers for Disease Control and Prevention will remain flat.
Vose: “Are We Ready To Care For These Patients?
Julie Vose, president of the American Society of Clinical Oncology, addressed the opening session of the society’s annual meeting in Chicago, discussing the themes of her year in office, the coming changes in federal cancer research and Medicare reimbursement, and the progress made over the society’s past 52 years.
|Safety Bills on Morcellators, |
Essure Introduced in House
Two House measures introduced earlier this week aim to strengthen federal requirements for reporting adverse outcomes caused by medical devices and to increase access to legal recourse for patients harmed by Class III high-risk devices.
• Related Coverage of Power Morcellation
- Former NCI Director Samuel Broder to retire from Intrexon Corp.
Yoshinori Ohsumi wins Janssen research prize from Johnson & Johnson
Five Pew-Stewart cancer research scholars announced
Susan G. Komen names 16 new Komen Scholars
American Hospital Dubai joins Mayo Clinic Care Network
University of Kentucky joins TriNetX
Roswell Park forms for-profit biotechnology company
CDC publishes Youth Risk Behavior Survey showing historic low smoking rates